High plasminogen activator inhibitor 1 (PAI-1) levels are associated with a
n increased cardiovascular risk of atherothrombosis. Furthermore, increased
plasma PAI-1 levels are associated with dyslipidemia, hyperinsulinemia and
hypertension. This association between PAI-1 and metabolic components of t
he Metabolic Syndrome could explain the predisposition of insulin resistant
patients to atherothrombosis. Recent studies have suggested that visceral
adipose tissue might be the link between elevated plasma PAI-1 and insulin
resistance in the Metabolic Syndrome. Indeed, visceral adipose tissue was p
roposed as a potentially important source of PAI-1 in humans. However, in l
ight of recent studies, visceral adipose tissue appears to be involved in t
he increase of plasma PAI-1 via the metabolic disorders usually associated
with central obesity, rather than directly. High plasma PAI-1 levels are un
doubtedly related to insulin resistance, and the mechanisms which could exp
lain such an increase in the Metabolic Syndrome appear to be multifactorial
and remain to be elucidated. These mechanisms may involve several metaboli
c disorders such as hyperinsulinemia, dyslipidemia, impaired glucose tolera
nce and hypertension, which would favor PAI-1 synthesis and release from di
fferent cell types. Copyright (C) 2000 John Wiley & Sons, Ltd.